Adv Ther (2017) 34:2648–2660 DOI 10.1007/s12325-017-0641-5 ORIGINAL RESEARCH Evaluation of the Efﬁciency of Single-Inhaler Combination Therapy with Budesonide/Formoterol Fumarate in Patients with Bronchial Asthma in Daily Clinical Practice . . . Michał Pirozyn _ ´ ski Piotr Hantulik Agnieszka Almgren-Rachtan Jerzy Chudek Received: October 2, 2017 / Published online: November 8, 2017 The Author(s) 2017. This article is an open access publication (age 49.8 ± 17.9 years) with asthma treated with ABSTRACT Bufomix Easyhaler for at least 14 days before enrolment. Asthma control was assessed during Introduction: The effectiveness of single-in- three subsequent visits with 8–12-week intervals haler budesonide/formoterol fumarate combi- on the basis of the Asthma Control Test (ACT). nation therapy for asthma has been previously Adherence was assessed with the Medication shown for the original product. The aim of this Adherence Questionnaire. In addition, patient nonrandomized, open-label, postauthorization satisfaction with Bufomix Easyhaler was efﬁcacy study (PAES) real-life clinical assessment scored, and adverse drug reactions were was to evaluate the clinical effectiveness of a recorded. second product (Bufomix Easyhaler ) in the Results: The percentage of patients with daily clinical practice of asthma therapy. well-controlled asthma or total control of Methods: This multicenter PAES was conducted asthma (ACT
Advances in Therapy – Springer Journals
Published: Nov 8, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera